This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Sep;188(3):809.

doi: 10.1016/j.juro.2012.05.064. Epub 2012 Jul 20.

Re: The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up

Patrick C Walsh

PMID: 22883757
DOI: 10.1016/j.juro.2012.05.064

Comment

Re: The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up

Patrick C Walsh. J Urol. 2012 Sep.

. 2012 Sep;188(3):809.

doi: 10.1016/j.juro.2012.05.064. Epub 2012 Jul 20.

Author

Patrick C Walsh

PMID: 22883757
DOI: 10.1016/j.juro.2012.05.064

No abstract available

PubMed Disclaimer

Comment on

The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.
Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, Walsh PC, Eisenberger MA. Antonarakis ES, et al. BJU Int. 2012 Jan;109(1):32-9. doi: 10.1111/j.1464-410X.2011.10422.x. Epub 2011 Jul 20. BJU Int. 2012. PMID: 21777360 Free PMC article.

Similar articles

Prostate specific antigen recurrence after definitive therapy.
Freedland SJ, Moul JW. Freedland SJ, et al. J Urol. 2007 Jun;177(6):1985-91. doi: 10.1016/j.juro.2007.01.137. J Urol. 2007. PMID: 17509277 Review.
Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
Soergel TM, Koch MO, Foster RS, Bihrle R, Wahle G, Gardner T, Jung SH. Soergel TM, et al. J Urol. 2001 Dec;166(6):2198-201. J Urol. 2001. PMID: 11696735
Radical prostatectomy for clinical stage T3a disease.
Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC. Freedland SJ, et al. Cancer. 2007 Apr 1;109(7):1273-8. doi: 10.1002/cncr.22544. Cancer. 2007. PMID: 17315165
Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance.
Sengupta S, Christensen CM, Zincke H, Slezak JM, Leibovich BC, Bergstralh EJ, Myers RP, Blute ML. Sengupta S, et al. J Urol. 2006 Aug;176(2):559-63. doi: 10.1016/j.juro.2006.03.086. J Urol. 2006. PMID: 16813889
Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy.
Sandler HM, Eisenberger MA. Sandler HM, et al. J Urol. 2007 Sep;178(3 Pt 2):S20-4. doi: 10.1016/j.juro.2007.04.034. Epub 2007 Jul 20. J Urol. 2007. PMID: 17644123 Review.

See all similar articles

Cited by

Targeted AKT Inhibition in Prostate Cancer Cells and Spheroids Reduces Aerobic Glycolysis and Generation of Hyperpolarized [1-¹³C] Lactate.
Tee SS, Suster I, Truong S, Jeong S, Eskandari R, DiGialleonardo V, Alvarez JA, Aldeborgh HN, Keshari KR. Tee SS, et al. Mol Cancer Res. 2018 Mar;16(3):453-460. doi: 10.1158/1541-7786.MCR-17-0458. Epub 2018 Jan 12. Mol Cancer Res. 2018. PMID: 29330287 Free PMC article.
SU6668 modulates prostate cancer progression by downregulating MTDH/AKT signaling pathway.
Qian B, Yao Y, Liu C, Zhang J, Chen H, Li H. Qian B, et al. Int J Oncol. 2017 May;50(5):1601-1611. doi: 10.3892/ijo.2017.3926. Epub 2017 Mar 22. Int J Oncol. 2017. PMID: 28339027 Free PMC article.
In Vitro Study of Calcium Microsecond Electroporation of Prostate Adenocarcinoma Cells.
Kiełbik A, Szlasa W, Michel O, Szewczyk A, Tarek M, Saczko J, Kulbacka J. Kiełbik A, et al. Molecules. 2020 Nov 19;25(22):5406. doi: 10.3390/molecules25225406. Molecules. 2020. PMID: 33227916 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources